This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Webster, L. K Articles by Millward, M. J Search for Related Content PubMed Articles by Webster, L. K Articles by Millward, M. J Social Bookmarking                   What's this?

Review : Cremophor: Pharmacological activity of an "inert" solubiliser

Pharmacology and Developmental Therapeutics Unit, Trescowthick Research Laboratories

David M Woodcock, PhD

Pharmacology and Developmental Therapeutics Unit, Trescowthick Research Laboratories

Danny Rischin, MBBS, FRACP

Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, St. Andrews Place, East Melbourne, Victoria 3002, Australia

Michael J Millward, MBBS, FRACP

Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, St. Andrews Place, East Melbourne, Victoria 3002, Australia

Objective. To provide an overview of the known pharmacological activity of the solvent for pacli taxel, Cremophor, and the implications for therapy with paclitaxel.

Data Sources. Following an outline of the chemistry of Cremophor and its potential to cause hypersensitivity, we present a summary of our own results from studies on the effect of Cremophor as an MDR modulator.

Data Extraction. The pharmacokinetic inter actions of paclitaxel and Cremophor are discussed, with reference to our own preclinical and clinical studies of Cremophor, and literature reports of altered drug disposition following combination therapy with paclitaxel are examined.

Data Synthesis. Cremophor is not an inert solubiliser. Cremophor may contribute to drug interactions by altering drug disposition, and it has the ability to modulate multidrug resistance. As a consequence of the presence of Cremophor in the paclitaxel formulation, the use of paclitaxel should be considered as the administration of two agents.

Key Words: Cremophor • drug interactions; paclitaxel • multidrug resistance • pharmaco kinetics.

Journal of Oncology Pharmacy Practice, Vol. 3, No. 4, 186-192 (1997)
DOI: 10.1177/107815529700300402


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?